Delving into the Latest Updates on Erythropoietin(Stem Cell Therapeutics) with Synapse

Overview

Basic Info

Drug Type

Colony-stimulating factors

Synonyms-

Target

EPO receptor

Action

agonists

Mechanism

EPO receptor agonists(Erythropoietin receptor agonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication-

Inactive Indication

Stroke

Originator Organization

Stem Cell Therapeutics

Active Organization-

Inactive Organization

Stem Cell Therapeutics

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Therapeutic protein hormones such as Erythropoietin and Gonadotrophins have historically utilised in vivo bioassays for potency assignment. In line with 3 R's principles for animal research, manufacturers and regulatory authorities alike are continually seeking to implement in vitro alternatives to animal assays wherever possible. However, these proteins are heavily glycosylated, giving rise to an inverse correlation of in vivo and in vitro biological activities, which complicates the transition away from in vivo bioassays for potency assignment. Whilst manufacturers are actively pursuing the development of alternatives to in vivo bioassays for product quality control, these efforts inevitably result in product-specific approaches, which are unlikely to be representative of all versions of the same product from different manufacturers. This presents a further challenge for organisations tasked with ensuring harmonisation of dosage between products from different manufacturers, through provision of documentary (pharmacopoeial monographs) and physical (assay calibrators) standards, as such resources must be suitable for all licensed versions of a product. This review will describe these challenges, and the product-specific approaches which have been implemented by manufacturers, and propose a framework aimed at mitigating the risks associated with the wider introduction of in vitro alternatives to in vivo potency assays.

01 May 2025·Brazilian Journal of Anesthesiology (English Edition)

Preoperative iron supplementation in non-anemic patients undergoing major surgery: a systematic review and meta-analysis

Review

Author: Miranda, Cesar de Araujo ; De Carli, Daniel ; Meletti, Jose Fernando Amaral ; Montes, Lucas Felix ; Gomes, Italo Pires ; Toledo, Fabio Vieira ; Sakashita, Renato Makoto ; Togo, Herman Yuri Almeida ; Tiburcio, Rafael Santos

BACKGROUNDBlood transfusions are associated with increased morbidity and mortality, and maintaining global blood supplies can be a challenge. This systematic review investigates the impact of preoperative iron supplementation on the risk of blood transfusion among non-anemic patients undergoing major surgeries.METHODSWe conducted a systematic search of PubMed, Embase, and Cochrane Central for randomized controlled trials published up to May 2024. Studies involving the use of erythropoietin, or patients already using iron supplementation when trial randomization was conducted were excluded. Outcomes assessed included the number of individuals who received blood transfusions, and mean hemoglobin levels at the first day and by the first postoperative week.RESULTSA total of 1,162 non-anemic patients from 9 studies were included. Of these, 54% received preoperative iron supplementation. The average age was 71 years, and 44% were women. Preoperative iron supplementation was associated with a significantly lower risk of receiving a blood transfusion (OR = 0.54; 95% CI 0.40 to 0.75; p < 0.001). At the first postoperative day, the iron supplementation group had significantly higher mean hemoglobin levels compared to the no-treatment group (MD = 0.22 g.dL^-1; 95% CI 0.02 to 0.42; p = 0.03). However, the pooled results could not rule out the null hypothesis for the difference in mean hemoglobin levels throughout the first week (MD = 0.12 g.dL^-1; 95% CI -0.12 to 0.35; p = 0.34).CONCLUSIONPreoperative intravenous iron supplementation in non-anemic patients undergoing major surgeries, particularly cardiac procedures, significantly reduces transfusion requirements. However, the benefits of oral iron remain uncertain, and further research is warranted to establish standardized perioperative supplementation protocols.PROSPERO IDENTIFIERCRD42024552559.

18 Apr 2025·Science Advances

A direct effect of the hematocrit on blood glucose: Evidence from hypoxia- and erythropoietin-treated mice

Article

Author: Pöltl, Lisa ; Kaplanian, Mairam ; Klimek, Peter ; Müller, Antonia M. S. ; Kautzky-Willer, Alexandra ; Abu Eid, Sameer ; Stemmer, Kerstin ; Suzuki, Norio ; Dürr, Sabine ; Yamamoto, Masayuki ; Fürnsinn, Clemens ; Scherer, Thomas ; Koldyka, Oliver ; Metz, Matthäus ; Kaya, Ayperi ; Prager, Gerhard ; Hackl, Martina T. ; Nusko, Laura ; Rivelles, Elisa ; Luca, Andreea C. ; Windberger, Ursula ; Ablaza, Kathleen ; Zeyda, Maximilian ; Chami, Rime ; Leutner, Michael ; Steinacher, Daniel ; Tschare, Claudia ; Beghini, Marianna ; Höbler, Anna-Lena ; Nics, Lukas ; Moriggl, Richard ; Bilban, Martin ; Gensthaler, Lisa ; Helbich, Thomas H. ; Schönecker, Stefanie S.

Blood glucose is lower in mountain dwellers living under low partial oxygen pressure. We show that obese mice maintained under hypoxia exhibit a delayed but distinct decrease in blood glucose with improved insulin sensitivity, which is independent of changes in body weight. This effect of hypoxia is mediated by erythropoiesis and is a direct result of the rising hematocrit, which could be due to erythrocytes acting as carriers of glucose units in the blood. Glucose lowering by the red cell mass is evidenced by a prompt decrease in glycemia in mice receiving a blood transfusion. Furthermore, life under hypoxia as well as treatment with erythropoietin reduce glycemia also in mice expressing the erythropoietin receptor exclusively in hematopoietic cells, which contrasts with previous assumptions attributing metabolic actions of erythropoietin to direct action on nonhematopoietic tissues. Our results provide a rationale for associations between hematocrit and blood glucose in humans under anti-anemic therapy, polycythemia, smoking, and high-altitude exposure.

100 Deals associated with Erythropoietin(Stem Cell Therapeutics)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Stroke	Phase 2	United States	Stem Cell Therapeutics	01 Aug 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2024	Not Applicable	Myelodysplastic Syndromes	228	Erythropoietin stimulating agents (ESAs)	edesvxxsbd(yqyrtkfndj) = zripvviimd xvtnywasdi (ndjkykgysl )	-	14 May 2024
ISN WCN2022	Not Applicable	-	-	ERYTHROPOIETIN (Pre-remedial)	xcvlmjvvyx(zmukixkpal) = erratic uqltghzvfk (ppjxjcqfes ) View more	-	01 Feb 2022
				ERYTHROPOIETIN (Post-remedial)
EHA2019	Not Applicable	Myelodysplastic Syndromes	177	Erythropoietin	(ssxjjzoqpq) = ilzxnhcsrj glxxueuagu (waruzqzkqp ) View more	-	16 May 2019
				Erythropoietin (Pack cell transfusion)	(ssxjjzoqpq) = encgniiapp glxxueuagu (waruzqzkqp ) View more
EHA2019	Not Applicable	Myelodysplastic Syndromes	45	Group A (sodium ferrigluconate)	vfdbyzpuub(bymrrmhylt) = yzozmaauaa cyxjlvnumb (jhvjftfmpn ) View more	-	16 May 2019
				Group B (sucrosomial iron)	vfdbyzpuub(bymrrmhylt) = naumzahlgu cyxjlvnumb (jhvjftfmpn ) View more
EHA2015	Not Applicable	Myelodysplastic Syndromes	107	ERYTHROPOIETIN (No support)	(sfozhkjwxe) = gxvydfqyzq jvlgbgiccz (jxftgqizbw ) View more	-	21 May 2015
				Epo support	(sfozhkjwxe) = nqmacuvdjm jvlgbgiccz (jxftgqizbw ) View more
ASN2013	Not Applicable	Anemia of renal disease \| Kidney Failure, Chronic	36	Darbepoetin Alpha	iglgezivso(ftueziqtiz) = bqrrcafmbl ygrsylbnag (qcuixfkgfd ) View more	Positive	05 Nov 2013
				Continuous Erythropoietin Receptor Activator	iglgezivso(ftueziqtiz) = bcfdadgftp ygrsylbnag (qcuixfkgfd ) View more
ASN2013	Not Applicable	-	-	Erythropoietin	ibujysblrx(cnjypjxsvq) = pchgpevdgl tvphafucjp (zbhoczmarw ) View more	-	05 Nov 2013
				Control (No EPO)	fgzbjzlwdf(nxlxpkmine) = mzqulfvaoe imshjrqgjx (mivighhsgp )
ASCO2013	Not Applicable	Anemia	-	erythropoietin-stimulating agents (Responder)	enalxcpfzu(umdzebnmgy) = gsuskbbqos srswokoqnv (okqtivossc )	-	20 May 2013
ASN2012	Not Applicable	BMC \| EPO	16	Erythropoietin	whpjhyyhrg(gljusvcplv) = nndwubqqpk eqqflvsbny (oagmscbxfd, 1.73) View more	Negative	30 Oct 2012
				Saline	whpjhyyhrg(gljusvcplv) = ahpbtdtzrb eqqflvsbny (oagmscbxfd, 4.56) View more
SAP100 (ERA2012)	Not Applicable	Reperfusion Injury BMC	16	Erythropoietin	(otqhqencyz) = mudjdbloob lovogfhjbi (vmrlqjoxrq, 0.20) View more	Negative	01 May 2012
				Saline solution	(otqhqencyz) = swwgtsreol lovogfhjbi (vmrlqjoxrq, 0.16) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data